论文部分内容阅读
糖皮质激素性骨质疏松症（GIOP）是临床最常见的继发性骨质疏松症，重视GIOP的防治刻不容缓。2013年中华医学会风湿病学分会制定了我国GIOP诊治专家共识。近年来，GIOP在流行病学、评估体系和防治药物等方面取得了巨大进展。同时，鉴于糖皮质激素临床应用非常广泛，2020年由中国医师协会风湿免疫科医师分会、中华医学会风湿病学分会、中华医学会骨质疏松和骨矿盐疾病分会及国家皮肤与免疫疾病临床医学研究中心组成多学科团队，对既往共识进行了更新，采用推荐意见分级的评估、制订及评价（GRADE）分级体系，对骨折风险的评估体系、分层治疗、药物转换和维持减停，以及特殊人群防治等临床问题，给出了较为详细的循证推荐，旨在进一步加强GIOP防治的规范性，提高以患者为中心的医疗服务质量。“,”Glucocorticoid induced osteoporosis (GIOP) is the most common secondary osteoporosis. The prevention and treatment of the disease need urgent attention. In 2013, the Chinese Rheumatology Association of Chinese Medical Association proposed the Chinese consensus on the diagnosis and treatment of GIOP. Recently, great progress was harvested in epidemiology, fracture risk assessment and pharmaceutical therapy of GIOP. Because of the wide usage of glucocorticoids, a multidisciplinary team has updated the consensus of GIOP under the leadership of several scientific and academic committees. Applying the grading of recommendations assessment, development and evaluation (GRADE) approach, this consensus provides detailed recommendations for several important issues such as stratified assessment of fractures, treatments under different stratification, conversion, maintenance and withdraw, and management of special patients. This consensus is intended to serve as a tool for Chinese clinicians to standardize prevention and treatment of the disease and to improve medical care for these patients.